Physician Wealth Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Physician Wealth Advisors’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$527	Buy	+48	New	+$545	﹤0.01%	2204

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return

Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return

Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

WoodTrust Financial Wisconsin Rapids, Wisconsin $825M AUM 20.13% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Physician Wealth Advisors's TLX Position: Q3 2026 in Review

Physician Wealth Advisors opened a new position in Telix Pharmaceuticals (TLX) in Q3 2026: 48 shares worth $527. The stake represents ﹤0.01% of the portfolio and ranks #2204 among its holdings.

34 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

Physician Wealth Advisors held 48 shares of Telix Pharmaceuticals worth $527 as of Q3 2026.
Telix Pharmaceuticals was a new Physician Wealth Advisors position in Q3 2026.
Telix Pharmaceuticals made up ﹤0.01% of Physician Wealth Advisors's portfolio in Q3 2026, its #2204 holding.
34 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on Physician Wealth Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.